In this week’s video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not yet been reduced.

BOTTOM LINE:
The cost of drugs is important to all of the myeloma community, and the IMF will continue to take part in discussing this.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
New Year, New Opportunities
Next Post
Top Five Trends in Myeloma News for 2018

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.